AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02647086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Cytochrome P450 substrate
Study NCT01132482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: During the course of the study, patients will receive 4 weeks of therapy: 28 days of placebo orally t.i.d. or 28 days of days of sildenafil orally t.i.d. Dosing of sildenafil will be escalated after the first week (20 mg orally t.i.d for the first week, then subjects will take 40 mg orally t.i.d. for 3 weeks). Patients not tolerating dose escalation will be discontinued from the study.
Study NCT01132482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receiving placebo will have sham dose escalation to maintain blinding.
Study NCT02901535 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spirometry
Description: Spirometry in baseline
Study NCT02901535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spirometry
Description: Spirometry in baseline
Study NCT02901535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telemonitoring
Description: telemonitoring (phone call nurse - 45 and 90 days)
Study NCT02901535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: teleconsultation
Description: teleconsultation (general practioner received phone call to respiratory care)
Study NCT02901535 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spirometry - 20 weeks
Description: Spirometry (20 weeks)
Study NCT02901535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spirometry - 20 weeks
Description: Spirometry (20 weeks)
Study NCT02093338 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus fermentum CECT5716
Study NCT02093338 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: maltodextrin
Description: Placebo
Study NCT01195493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Essential Oils solution
Description: (Essential oils solution, Listerine®, Johnson \& Johnson) to use twice a day (2 x 20 ml) following daily mechanical oral hygiene practices
Study NCT01195493 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: negative control solution
Description: this solution would be used twice per day (2 x 20 ml) following daily home care.
Study NCT02821364 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Advanced Life Support
Description: IV FLUIDS, INTUBATION
Study NCT00810784 — intervention group
Intervention type: BEHAVIORAL
Intervention: Education
Description: (1) a risk-assessment tool completed at the time of a hospital admission, (2) structured educational sessions on VTE prevention, and (3) audit-feedback where institutional data was reviewed during the educational sessions. These sessions were given once to the clinical pharmacists and on three separate occasions to the medicine house officers.
Study NCT02816619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Physical Activity coaching program
Study NCT02816619 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Free practice of physical activity
Study NCT02641717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vaginal swab
Study NCT00294255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: risperidone will be administered 1-3mg pills, each night, for up to 20 weeks
Study NCT03222414 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive BP recording with conical Ultracheck Curve BP cuff
Description: Non-invasive SBP, DAP and MAP will be measured in both arms using conical Ultracheck Curve BP cuff
Study NCT03222414 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive BP recording with conical Ultracheck Curve BP cuff
Description: Non-invasive SBP, DAP and MAP will be measured in both arms using conical Ultracheck Curve BP cuff
Study NCT03222414 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive BP recording with traditional cylindrical BP cuff
Description: Non-invasive SBP, DAP and MAP will be measured in both arms using traditional cylindrical BP cuff
Study NCT03222414 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive BP recording with traditional cylindrical BP cuff
Description: Non-invasive SBP, DAP and MAP will be measured in both arms using traditional cylindrical BP cuff
Study NCT03222414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct invasive arterial pressure
Description: Direct invasive arterial pressure readings will be recorded simultaneously with non-invasive measurements
Study NCT03222414 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Direct invasive arterial pressure
Description: Direct invasive arterial pressure readings will be recorded simultaneously with non-invasive measurements
Study NCT02460341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron
Description: Ondansetron 8mg, 16mg, 24mg
Study NCT02460341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo pill
Study NCT01501552 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training and support (T&S)
Description: Two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. The telephone call will be offered to one of the GPs ('leader'). Depending on the needs of the PHCU, one additional face to face training (1 to 2 hours) may be offered. The time interval between meetings will be on average 2 weeks. The training sessions will address improving knowledge, skills, attitudes, and perceived barriers and facilitators by combining theory and practice-based training.
Study NCT01501552 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial incentive
Description: Groups will receive a financial incentive depending on their screening and brief intervention activities. They will be paid for the performance, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
Study NCT06113276 — intervention group
Intervention type: RADIATION
Intervention: Low dose computed tomography to evaluate biomechanical parameters in the lung
Description: In the participating to the study, response to PEEP increase and tidal inflation are evaluated with a software computing biomechanical parameters (tidal hyperinflation and lung recruitability). Tidal hyperinflation and recruitment are computed on CT images acquired within 72 hours after ARDS onset or with 72h after ECMO onset.
Study NCT01501552 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-SBI (online screening and brief intervention)
Description: Referring identified at-risk patients to an approved e-SBI programme, which will be either country specific (where these exist) or based on the WHO e-SBI programme (Poland).
Study NCT02399202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: osilodrostat
Study NCT02291549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S8 Sinus Implant
Description: In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
Study NCT03222947 — intervention group
Intervention type: GENETIC
Intervention: Deoxyribonucleic acid analysis
Description: This study consists in the high throughput exome sequencing and subsequent genetic bio-analysis of 19 deoxyribonucleic acid samples from 6 families, already collected and consented, including patients diagnosed with a Taybi-Linder syndrome and their relatives (parents and/or siblings).
Study NCT00580762 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-y gastric bypass (RYGB)
Study NCT00580762 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-y gastric bypass (RYGB)
Study NCT04405245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost ophthalmic solution
Description: Latanoprost opthalmic solution to be dosed once daily
Study NCT04405245 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Latanoprost ophthalmic solution
Description: Latanoprost opthalmic solution to be dosed once daily
Study NCT04405245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-9778 4%
Description: Razuprotafib opthalmic solution
Study NCT04405245 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo for razuprotafib opthalmic solution
Study NCT05993962 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified yoghurt
Description: Food-grade vitamin B12 in the form of methylcobalamin (purity: 99%) was used for fortification. Yoghurts were Greek-style and locally produced by a yoghurt company in British Columbia, Canada. The pre-measured vitamin B12 was added into yoghurt vats in amounts that corresponded to the chosen dosage (50 µg of B12 per 150 g). The yoghurt was packaged into white cups, each containing 150 grams of yoghurt, labelled with the date of production and study code.
Study NCT05993962 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control yoghurt
Description: Yoghurts were locally produced by a yoghurt company in British Columbia, Canada. Yoghurts produced were Greek-style and packaged into white cups, each containing 150 grams of yoghurt, labelled with the date of production and study code.
Study NCT02986113 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAPS tailored multimedia patient activation program
Study NCT02986113 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep hygiene video
Description: 3 minute video on sleep hygiene produced by HealthiNation
Study NCT02986113 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone evidence-based follow-up care
Description: 3 months of suicide-focused collaborative mental health care, directed by a supervising psychiatrist and implemented by a care manager working with the patient and their primary care provider
Study NCT02986113 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone evidence-based follow-up care
Description: 3 months of suicide-focused collaborative mental health care, directed by a supervising psychiatrist and implemented by a care manager working with the patient and their primary care provider
Study NCT02986113 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Commitment to Living for Primary Care
Description: Brief (30 minutes total time) video modules presenting participating patients' primary care providers with a patient-centered framework for suicide risk assessment and intervention
Study NCT02986113 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Commitment to Living for Primary Care
Description: Brief (30 minutes total time) video modules presenting participating patients' primary care providers with a patient-centered framework for suicide risk assessment and intervention
Study NCT04491851 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 PET/CT
Description: Patients will undergo PET/CT using 68Ga-NODAGA-LM3 (40ug peptide/150-200MBq) and 68Ga-DOTA-LM3 (40ug peptide/150-200MBq) on two consecutive days. The scan will be acquired at 1hour post-injection.
Study NCT01632527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HuCNS-SC cells
Description: HuCNS-SC cells transplantation directly into the subretinal space of one eye (Study eye) in a single transplant procedure.
Study NCT04491851 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-LM3 and 68Ga-NODAGA-JR11 PET/CT
Description: Patients will undergo PET/CT using 68Ga-NODAGA-LM3 (40ug peptide/150-200MBq) and 68Ga-NODAGA-JR11 (40ug peptide/150-200MBq) on two consecutive days. The scan will be acquired at 1hour post-injection.
Study NCT03836677 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: BGF
Description: Treatment with Budesonide/Glycopyrronium/FormoterolFumarate
Study NCT03836677 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: GFF
Description: Treatment with Glycopyrronium/Formoterol Fumarate
Study NCT02350504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full interactive instruction
Description: This is a prospective randomized controlled trial in which the level of the child's exposure to instruction is controlled according to the group he is attributed to. The children are divided randomly, each Sunday (the day there is an available anesthesia staff) we change the extent of the instruction. In the intervention group, we use Full interactive instruction- which include an instructional booklet, a movie and a simulator's practice.
Study NCT06421922 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Group 1 received a regular constipation diet
Description: Group 1 received only regular constipation diet, the constipation diet included 2 litres of water, 2 portions of vegetables, 3 portions of fruits and legumes 2 times a week. Followed 8 weeks.
Study NCT06421922 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Group 2 received a constipation diet rich in soluble fiber
Description: Soluble fiber (resistant starch) (5 g/day) was added to the constipation diet in group 2 as 1 sachet/day (5 g/day) during the initial 4 weeks and 2 sachets/day (10 g/day) in the following 4 weeks.
Study NCT06421922 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Group 3 received a constipation diet supplemented with probiotic yogurt.
Description: Bifidobacterium İnfantis 35624 (B. İnfantis 35624)\&#34; strain, which is specific to IBS, was added to yogurt in group 3, consumed before the lunch. The follow-up period was 8 weeks.
Study NCT03370562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Administration of 10 mcg intravenous dexmedetomidine
Study NCT03370562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of normal saline
Study NCT02195167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily
Description: Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily. The planned dose for the first cohort is 1mg. There will be no more than a 2-fold increase in dose increase in dose between consecutive dose cohorts up to 8 mg, and dose cohorts beyond the 8 mg level will increment no more than 4mg. The maximum dose will not exceed 32mg. The language should precede the text that is currently there
Study NCT03292276 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amadeo Training
Description: To understand the cortical modifications related to movement preparation and execution after robot-assisted training we will study the EEG modifications of cortical activity using time-frequency event-related EEG and task-related coherence (TRCoh).~Friedman ANOVA with post-hoc t-test (corrected for multiple comparisons) will be used to assess the significance of training-induced changes in the two groups.
Study NCT03292276 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Amadeo Training
Description: To understand the cortical modifications related to movement preparation and execution after robot-assisted training we will study the EEG modifications of cortical activity using time-frequency event-related EEG and task-related coherence (TRCoh).~Friedman ANOVA with post-hoc t-test (corrected for multiple comparisons) will be used to assess the significance of training-induced changes in the two groups.
Study NCT00673283 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bi-plane chest radiography
Description: Bi-plane radiography of the thorax
Study NCT01786252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human chorionic gonadotropin (hCG)
Description: 500IU of hCG diluted to a final volume of 50ul in IVF media (Global-trademark)
Study NCT01786252 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator (for hCG)
Description: 50ul of IVF medium (Global-trademark) to mimic hCG infusion
Study NCT02809963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: 50 mg tablets, oral use.
Study NCT02809963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 mg tablets, oral use
Study NCT01480401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low-sodium diet (1500 mg daily)
Study NCT03688100 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Activation Therapy
Description: The therapy group will consist of an introductory in person 50-minute treatment session, followed by 12 weekly telephone 50-minute outpatient treatment sessions, then 3 monthly telephone 50-minute outpatient maintenance sessions. A typical BA session will last 50 minutes and include a review of the previous session and completed daily monitoring record forms, an in-depth discussion of life areas and value, and verbal reinforcement of activity engagement.
Study NCT03688100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medication Management
Description: Collaborative care model will be used. The medication management group will meet with the patient in a one 50 minute in person introductory antidepressant medication treatment session to educate the patient about depression and medication options. Patients will get prescribed a standard of care anti-depressant medication by treating physician, followed by 12 weekly follow up telephone visits, then on a monthly basis for 3 months, and then as needed thereafter.
Study NCT04079881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: to give pre-prandial and post-prandial insulin (will use patient insulin dose patient use at home) to patients with T1D and evaluate the response of post-prandial glucagon and post-prandial hyperglycemia.
Study NCT03907462 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART 2.0
Description: SMART 2.0 uses a fully integrated system of modalities that includes: 1) a popular consumer-level wearable, wireless scale, and corresponding app; 2) a highly tailored and interactive text messaging system; 3) multiple social media streams; 4) social network mechanisms of influence; and 5) technology-mediated health coaching.
Study NCT04005079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Description: 2% pilocarpine in the postoperative period in addition to standard postoperative drops (Prednisolone acetate and Ofloxacin)
Study NCT04005079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofloxacin
Description: Standard of care
Study NCT04005079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Description: Standard of care
Study NCT04005079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Standard of Care
Study NCT04005079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Standard of Care
Study NCT01184417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 mg/kg IV phenobarbital in 100 ml saline
Description: 10 mg/kg IV phenobarbital in 100 ml saline
Study NCT01184417 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 100 m l saline
Study NCT01262664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prohibitin-TP01
Description: Starting dose of 0.03 mg/kg as an injection under the skin 1 time each day for 28 days.
Study NCT00147004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocortisone sodium succinate
Description: 50 mg intravenous bolus every six hours for 5 days, then tapered to 50 mg intravenously every 12 hours for days 6-8, 50 mg every 24 hours for days 9-11 and then stopped
Study NCT00147004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00307866 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resovist (BAY86-4884, SH U 555 A)
Description: Single bolus injection, followed by MRI
Study NCT02218944 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Response Inhibition Training
Description: The primary purpose of this research is to examine the feasibility and efficacy of a smoking specific response inhibition training program in the context of a quit attempt. The task is based on a modified stop-signal task. The study utilizes a one-way nested design with three conditions.
Study NCT02218944 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Response Inhibition Training
Description: The primary purpose of this research is to examine the feasibility and efficacy of a smoking specific response inhibition training program in the context of a quit attempt. The task is based on a modified stop-signal task. The study utilizes a one-way nested design with three conditions.
Study NCT03110575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102 SL
Description: 2 x TNX-102 SL, 2.8mg tablets taken daily at bedtime for 12 weeks
Study NCT03779074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10d bismuth quadruple therapy
Description: rabeprazole 20 mg b.i.d. plus tripotassium dicitrate bismuthate 300 mg, tetracycline 500 mg and metronidazole 250 mg q.i.d. for 10 days
Study NCT03779074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14d hybrid therapy
Description: a dual regimen with rabeprazole 20 mg and amoxicillin 1 g b.i.d. for 7 days followed by a quadruple regimen with rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg b.i.d. for 7 days